Skip to main content

Daily Oral PrEP Has Highest Preference Ranking Among Young Men

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 12, 2023 -- Daily oral preexposure prophylaxis (PrEP) has the highest preference ranking among young men who have sex with men, according to a study recently published in the Journal of the International AIDS Society.

Katie B. Biello, Ph.D., M.P.H., from Brown University in Providence, Rhode Island, and colleagues surveyed 737 cisgender young men who have sex with men (age 15 to 24 years) without HIV. Participants completed a conjoint experiment comparing daily oral pills, event-driven oral pills, event-driven rectal douches, intramuscular injections, intravenous broadly neutralizing antibody (bnAb) infusions, and subcutaneous implants for PrEP; the products were ranked from the most to least preferred.

The researchers found that the highest preference ranking was for daily oral PrEP, followed by event-driven oral pills, injections, implants, bnAb infusions, and rectal douches (odds ratios, 0.89, 0.83, 0.48, 0.38, and 0.24, respectively). Differences in PrEP preferences were seen across age, insurance status, sexual behavioral, PrEP use history, HIV and sexually transmitted infection (STI) testing history, and STI diagnoses. Reasons for selecting the top product included ease of use for those who chose daily oral and daily event-driven pills (99 and 98.5 percent, respectively) and feeling more protected for those who chose injections and implants (95.4 and 100 percent, respectively). For those who chose bnAb infusions and rectal douches, the top reasons were not worrying about forgetting to take it (93.8 percent) and being able to stop taking it when they want (90.9 percent), respectively.

"Understanding preferences is important because we need to create interventions that connect people to their preferred delivery method," coauthor Pablo K. Valente, M.D., also from Brown University, said in a statement.

Two authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Cognitive Impairment Still Seen in Children, Teens With HIV

TUESDAY, April 30, 2024 -- Cognitive impairment persists in children and adolescents living with HIV even in the era of antiretroviral therapy (ART), according to research...

Pandemic Reignited Debate Regarding Physician's Obligation to Treat

MONDAY, April 29, 2024 -- There was a surge in ethics literature during COVID-19 advocating for the ethical acceptability of physicians refusing to treat, according to a study...

Coronary Artery Vessel Wall Thickness Increased for People Living With HIV

TUESDAY, April 16, 2024 -- Asymptomatic people living with HIV (PLWH) with a low risk for cardiovascular disease have increased coronary artery vessel wall thickness (VWT)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.